Sol-gel™: a patented technology for formulating ophthalmic hydrogels

Sol-gel™ is a patented technology for formulating ophthalmic hydrogels. It has the particularity of being completely liquid during manufacture and of gelling on application, more precisely on contact with the tear fluid, thanks to the gellan gum they contain.

The increase in viscosity in situ provides optimal patient comfort and extends the length of time that the ophthalmic drug acts; this allows a reduction in the amount of active ingredient delivered at each intake, thereby limiting potential undesirable side effects.

Benefits

  • Optimisation of diagnostic and pre-operative mydriasis induction
  • High bioavailability
  • Easy administration
  • Prolonged release
  • Improved ocular residence time
  • Reducing the required amount of active pharmaceutical ingredients administered by 4 to 8 compared to the conventional eye drop regimen
  • Molecules: hydrophilic excipients and compendia

Technology

  • Blow-Fill-Seal (BFS) or Preservative-free multidose (PFMD)
  • Preservative-free
  • Sterile

Product

Solmyd™ is the first application of our Solgel™ technology; it is a mydriatic hydrogel to optimize the induction of diagnostic and pre-operative mydriasis, which contains a combination of tropicamide and phenylephrine hydrochloride.

The pupil must be dilated (Mydriasis) prior to many ocular examinations and operations.

As of today, only mydriatic solutions are available; they require repeated instillations every few minutes, which is restrictive for patients and healthcare professionals.

Solmyd™ achieves mydriasis with a single instillation. The concentrations of tropicamide and phenylephrine hydrochloride in the drops are reduced compared to existing eye drops, reducing the adverse (cardiac) effects of phenylephrine on the heart  and providing a single dosage for adults and children.

Authorizations

All French sites are subject to inspections by European authorities, in order to manufacture products for the European markets. The Coutances site (France) is regularly inspected by the ANSM (Agence Nationale de Sécurité du Médicament), the FDA (Food Drug and Administration), ANVISA (Brazilian Agency) and other health authorities around the world.

Manufacturing plants

Coutances, France


 

Innovation

Blow-fill-seal

PFMD